# A Study of RG1662 in Adults and Adolescents With Down Syndrome (CLEMATIS)

> **NCT02024789** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 173 (actual)

## Conditions studied

- Down Syndrome

## Interventions

- **DRUG:** Placebo
- **DRUG:** RG1662
- **DRUG:** RG1662

## Key facts

- **NCT ID:** NCT02024789
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-05
- **Primary completion:** 2016-05-04
- **Final completion:** 2016-05-04
- **Target enrollment:** 173 (ACTUAL)
- **Last updated:** 2017-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02024789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02024789, "A Study of RG1662 in Adults and Adolescents With Down Syndrome (CLEMATIS)". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT02024789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*